Logo
Login
$SEPN
$44.14 +$2.76 (6.67%) Close

Company Executives

$SEPN Management Team

Dr. Jeffrey Tong

Chairman of the Board

Age 50
Compensation $129.3K USD
Sex Male

Dr. Jeffrey Finer

Chief Executive Officer

Director

Age 59
Compensation $4.720M USD
Sex Male

Ms. Elizabeth Bhatt

President

Age 57
Compensation $1.619M USD
Sex Female

Mr. Daniel Long

Senior Vice President - Drug Discovery

Age 52
Compensation $646.7K USD
Sex Male

Dr. Jae Kim

Chief Medical Officer

Age 55
Compensation $1.870M USD
Sex Male

Mr. Gil Labrucherie

Chief Financial Officer

Age 53
Compensation -
Sex Male

Ms. Samira Shaikhly

Chief People Officer

Age 55
Compensation $742.5K USD
Sex Female

Dr. Uwe Klein

Senior Vice President - Biological Sciences

Age 60
Compensation $578.5K USD
Sex Male

Board of Directors

From the proxy statement filed Apr 30, 2026
Directors
8
serving now
Independent
6 of 8
stated in the proxy
Average tenure
3.8 years
from year joined
CEO also chairs the board
No
Jeffrey Tong
Director Age On board Independent Committees Other public boards Pay Source
Shalini Sharp
51 2024
2 years
 Independent
Audit Committee · Chair
BeOne Medicines Ltd. Not stated
Jake Simson
40 2023
3 years
 Independent
Audit Committee
Bicara Therapeutics Inc. Not stated
Jeffrey Finer
CEO
 60 2021
5 years
 Not independent None stated None stated Paid as CEO
Jeffrey Tong
Board chair
 51 2019
7 years
 Independent
Nominating and Corporate Governance Committee
None stated Not stated
Bernard Coulie
60 2023
3 years
 Independent
Research and Development Committee
None stated Not stated
Abraham Bassan
41 2021
5 years
 Independent None stated Rani Therapeutics Holdings, Inc. Not stated
Alan Ezekowitz
72 2022
4 years
 Not independent
Research and Development Committee
Fulcrum Therapeutics, Inc. Not stated
Keith Gottesdiener
72 2025
1 year
 Independent None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 30, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans